VolitionRx (VNRX) – Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for VolitionRx (NYSE: VNRX):

• 11/22/2024 – VolitionRx had its “hold” rating reaffirmed by analysts at Benchmark Co..
• 11/20/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/12/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/4/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/27/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/19/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/11/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/3/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

VolitionRx Stock Down 8.7 %

Shares of VolitionRx stock traded down $0.07 during trading on Monday, hitting $0.73. The stock had a trading volume of 117,676 shares, compared to its average volume of 161,618. The stock has a 50 day simple moving average of $0.69 and a 200 day simple moving average of $0.68. The company has a market capitalization of $67.19 million, a PE ratio of -2.01 and a beta of 1.10. VolitionRx Limited has a 1 year low of $0.43 and a 1 year high of $1.23.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC grew its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.